Patents by Inventor James Wieler
James Wieler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10000568Abstract: The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.Type: GrantFiled: April 10, 2009Date of Patent: June 19, 2018Assignee: Cell Signaling Technology, Inc.Inventors: Ting-Lei Gu, Jiong Wu, Susan Kane, Jian Yu, Herbert Haack, James Wieler, Jun-Ming Cai, Victoria Rimkunas
-
Patent number: 8431130Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: GrantFiled: July 26, 2010Date of Patent: April 30, 2013Assignee: Abbott LaboratoriesInventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
-
Publication number: 20120093837Abstract: The invention discloses binding agents to the E746-A750 deletion and the L858R point mutations in the epidermal growth factor receptor (EGFR) molecule, and methods for use thereof, including methods for the diagnosis and treatment of cancer.Type: ApplicationFiled: April 10, 2009Publication date: April 19, 2012Inventors: Ting-Lei Gu, Jiong Wu, Susan Kane, Jian Yu, Herbert Haack, James Wieler, Jun-Ming Cai, Victoria Rimkunas
-
Patent number: 7968684Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: GrantFiled: November 12, 2004Date of Patent: June 28, 2011Assignee: Abbott LaboratoriesInventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
-
Publication number: 20100291088Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: July 26, 2010Publication date: November 18, 2010Applicant: Abbott LaboratoriesInventors: Tariq Ghayur, Boris Labkovsky, Jeffrey W. Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Singh Kang, Brad Hedberg
-
Publication number: 20090252746Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.Type: ApplicationFiled: May 14, 2008Publication date: October 8, 2009Applicant: Abbott LaboratoriesInventors: Peter J. DeVries, David H. Ostrow, Edward B. Reilly, Larry L. Green, James Wieler
-
Patent number: 7396913Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.Type: GrantFiled: October 10, 2003Date of Patent: July 8, 2008Assignee: Abbott LaboratoriesInventors: Peter J. DeVries, David H. Ostrow, Edward B. Reilly, Larry L. Green, James Wieler
-
Publication number: 20050147610Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: November 12, 2004Publication date: July 7, 2005Inventors: Tariq Ghayur, Boris Labkovsky, Jeffrey Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Kang, Brad Hedberg
-
Publication number: 20050100965Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.Type: ApplicationFiled: November 12, 2003Publication date: May 12, 2005Inventors: Tariq Ghayur, Boris Labkovsky, Jeffrey Voss, Larry Green, John Babcook, Xiao-chi Jia, James Wieler, Jaspal Kang, Brad Hedberg
-
Publication number: 20040175379Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.Type: ApplicationFiled: October 10, 2003Publication date: September 9, 2004Inventors: Peter J. DeVries, David H. Ostrow, Edward B. Reilly, Larry L. Green, James Wieler
-
Publication number: 20040071694Abstract: The present invention relates to antibodies and antibody fragments thereof that bind to and activate an erythropoietin receptor. The present invention also relates to methods of modulating the endogenous activity of an erythropoietin receptor in a mammal using said antibodies as well as pharmaceutical compositions containing said antibodies.Type: ApplicationFiled: October 14, 2002Publication date: April 15, 2004Inventors: Peter J. DeVries, Larry L. Green, David H. Ostrow, Edward B. Reilly, James Wieler